卷曲霉素的杂质在安全性和药代动力学方面存在差异。 - Suppr

Suppr

超能文献

The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles.

作者信息

Lee Sung Hak, Shin Jaekyu, Choi Jae Mook, Lee Eun Young, Kim Dal Hyun, Suh Jung-Woo, Chang Jun Hwan

出版信息

Int J Antimicrob Agents. 2003 Jul;22(1):81-3. doi: 10.1016/s0924-8579(03)00124-9.

DOI:10.1016/s0924-8579(03)00124-9

PMID:12842334

Abstract

摘要

相似文献

The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles.

Int J Antimicrob Agents. 2003 Jul;22(1):81-3. doi: 10.1016/s0924-8579(03)00124-9.

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. doi: 10.1128/AAC.01164-06. Epub 2007 May 21.

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin.

Pharm Res. 2008 Apr;25(4):805-11. doi: 10.1007/s11095-007-9381-6. Epub 2007 Jul 27.

Capreomycin oleate microparticles for intramuscular administration: Preparation, in vitro release and preliminary in vivo evaluation.

J Control Release. 2015 Jul 10;209:229-37. doi: 10.1016/j.jconrel.2015.05.001. Epub 2015 May 5.

A physiologically based pharmacokinetic model for capreomycin.

Antimicrob Agents Chemother. 2012 Feb;56(2):926-34. doi: 10.1128/AAC.05180-11. Epub 2011 Dec 5.

Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.

Int J Pharm. 2015 May 15;485(1-2):138-51. doi: 10.1016/j.ijpharm.2015.02.050. Epub 2015 Mar 10.

UV spectroscopy and reverse-phase HPLC as novel methods to determine Capreomycin of liposomal fomulations.

J Pharm Biomed Anal. 2004 Oct 29;36(2):249-55. doi: 10.1016/j.jpba.2004.06.015.

Capreomycin inhalable powders prepared with an innovative spray-drying technique.

Int J Pharm. 2014 Jul 20;469(1):132-9. doi: 10.1016/j.ijpharm.2014.04.042. Epub 2014 Apr 18.

Simple and scalable method for peptide inhalable powder production.

Eur J Pharm Sci. 2010 Jan 31;39(1-3):53-8. doi: 10.1016/j.ejps.2009.10.010. Epub 2009 Oct 30.

Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.

J Drug Target. 2009 Dec;17(10):777-87. doi: 10.3109/10611860903115308.

引用本文的文献

Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.

Antimicrob Agents Chemother. 2012 May;56(5):2612-8. doi: 10.1128/AAC.06145-11. Epub 2012 Feb 13.

A physiologically based pharmacokinetic model for capreomycin.

Antimicrob Agents Chemother. 2012 Feb;56(2):926-34. doi: 10.1128/AAC.05180-11. Epub 2011 Dec 5.

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. doi: 10.1128/AAC.01164-06. Epub 2007 May 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles.

Int J Antimicrob Agents. 2003 Jul;22(1):81-3. doi: 10.1016/s0924-8579(03)00124-9.

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. doi: 10.1128/AAC.01164-06. Epub 2007 May 21.

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin.

Pharm Res. 2008 Apr;25(4):805-11. doi: 10.1007/s11095-007-9381-6. Epub 2007 Jul 27.

Capreomycin oleate microparticles for intramuscular administration: Preparation, in vitro release and preliminary in vivo evaluation.

J Control Release. 2015 Jul 10;209:229-37. doi: 10.1016/j.jconrel.2015.05.001. Epub 2015 May 5.

A physiologically based pharmacokinetic model for capreomycin.

Antimicrob Agents Chemother. 2012 Feb;56(2):926-34. doi: 10.1128/AAC.05180-11. Epub 2011 Dec 5.

Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.

Int J Pharm. 2015 May 15;485(1-2):138-51. doi: 10.1016/j.ijpharm.2015.02.050. Epub 2015 Mar 10.

UV spectroscopy and reverse-phase HPLC as novel methods to determine Capreomycin of liposomal fomulations.

J Pharm Biomed Anal. 2004 Oct 29;36(2):249-55. doi: 10.1016/j.jpba.2004.06.015.

Capreomycin inhalable powders prepared with an innovative spray-drying technique.

Int J Pharm. 2014 Jul 20;469(1):132-9. doi: 10.1016/j.ijpharm.2014.04.042. Epub 2014 Apr 18.

Simple and scalable method for peptide inhalable powder production.

Eur J Pharm Sci. 2010 Jan 31;39(1-3):53-8. doi: 10.1016/j.ejps.2009.10.010. Epub 2009 Oct 30.

Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.

J Drug Target. 2009 Dec;17(10):777-87. doi: 10.3109/10611860903115308.

引用本文的文献

Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.

Antimicrob Agents Chemother. 2012 May;56(5):2612-8. doi: 10.1128/AAC.06145-11. Epub 2012 Feb 13.

A physiologically based pharmacokinetic model for capreomycin.

Antimicrob Agents Chemother. 2012 Feb;56(2):926-34. doi: 10.1128/AAC.05180-11. Epub 2011 Dec 5.

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. doi: 10.1128/AAC.01164-06. Epub 2007 May 21.